CN1383871A - Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases - Google Patents
Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases Download PDFInfo
- Publication number
- CN1383871A CN1383871A CN02113797A CN02113797A CN1383871A CN 1383871 A CN1383871 A CN 1383871A CN 02113797 A CN02113797 A CN 02113797A CN 02113797 A CN02113797 A CN 02113797A CN 1383871 A CN1383871 A CN 1383871A
- Authority
- CN
- China
- Prior art keywords
- monascus
- compositions
- monas cuspurpureus
- cuspurpureus went
- monacus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A composition of notoginseng and fermented red rice can be used to prevent and treat cardiac and cerebral vascular diseases effectively and safely. The raw material may be notoginseng and fermented red rice or their extractives, effective parts or effective components and the composite has the synergistic effect of the effective componnets. The said composition produced to medically acceptable preparation forms, such as tablet, capsule, granule, powder, etc. and may be used as health food or food additive.
Description
Affiliated field: medicine of the present invention and field of food are that the Radix Notoginseng and the Monas cuspurpureus Went of a kind of prevention or treatment cardiovascular and cerebrovascular disease is the compositions that raw material is formed.
Background technology: in recent years, along with growth in the living standard and social population's aging, cardiovascular and cerebrovascular disease, as coronary heart disease, acute cerebrovascular disease, peripheral blood vessel etc., sickness rate has the trend that raises year by year, serious harm human life health.
Cardiovascular and cerebrovascular disease is because of due to the atherosclerosis to a great extent, and atherosclerosis is the chronic disease due to the risk factor more than, and principal risk factor has: dyslipidemia, smoking, hypertension and diabetes etc.Therefore, from the treatment of starting with of several respects such as blood lipid regulation, blood pressure regulation, blood sugar regulation, the control of cardiovascular and cerebrovascular disease had the important clinical meaning.
Treating hyperlipidemia in the market mainly contains: Statins, the special class of shellfish, bile acid chelating agent and nicotinic acid class.Treat hypertensive medicine the most frequently used be: diuretic, beta-blocker, calcium antagonist, angiotensin converting enzyme inhibitor and α receptor blocking agent.The medicine of treatment diabetes has: biguanides, Alpha-glucosidase inhibitor and euglycemic agent---thiazolidinedione etc.With these medicines the control of cardiovascular and cerebrovascular disease has been obtained certain effect clinically, but it is remarkable to take side effect for a long time, and patient's body and mind is caused harmful effect.
Therefore, according to the characteristics that cardiovascular and cerebrovascular disease need be taken medicine for a long time, should adopt effectively and the little natural product of toxic and side effects is advisable.
Chinese patent application, application number: 00135783.2, name is called " a kind of natural composition and application thereof that prevents and treats cardiovascular and cerebrovascular disease ", and its compositions also relates to Radix Notoginseng and mycetogenetic hypolipidemic activity composition---lovastatin.Yet the Monas cuspurpureus Went effect for reducing blood fat is the synergistic result of multiple composition, and lovastatin is one of blood fat reducing effective ingredient in the Monas cuspurpureus Went, and this is the difference of patent of the present invention and foregoing invention patent.
Summary of the invention: at the deficiency of present control cardiovascular and cerebrovascular diseases medicament, the object of the present invention is to provide Radix Notoginseng, the fermented red rice composition of a kind of prevention or treatment cardiovascular and cerebrovascular disease, prevention that it can be effective, safe or treatment cardiovascular and cerebrovascular disease.
The present invention also aims to pass through medicine efficacy screening, prescription raw material and extract, effective site or effective ingredient are carried out different proportion relation researchs, find out and a kind ofly act on body, thereby can prevent and treat the proportion relation of the optimum feed stock of cardiovascular and cerebrovascular disease comprehensively by number of ways.
The present invention also aims on above research basis, develop a series of medicines that are easy to carry and take, health food or food additive.
Purpose of the present invention realizes by following measure:
With Radix Notoginseng and Monas cuspurpureus Went is raw material, by the dry matter weight Radix Notoginseng: Monas cuspurpureus Went=(10%～90%): the mixed of (90%～10%).
The fungus of above-mentioned generation Monas cuspurpureus Went can be monascus (Monacus anka), Mauve aspergillar (MonacusPurpureus), monascus (Monacus albidus) turns white, Bark monascus (Monacus barkeri), smoky gray monascus (Monacus fulignosus), red monascus (Monacus rubervam), rust monascus (Monacus rubiginosus), in monascus (Monacus serorubescens) and the Mucor shape monascus (Monacus mucoroides) any reddens.
Above-mentioned Radix Notoginseng (Panax notoginseng) and extract, effective site and effective ingredient all can be used as raw material; Monas cuspurpureus Went and extract thereof, effective site and effective ingredient all can be used as raw material.
Said composition can be an acceptable preparation medically, as, tablet, capsule (soft capsule or hard capsule), granule, powder etc.Said composition can be applicable to health food or food additive.
The effect of below introducing Radix Notoginseng in the prescription, Monas cuspurpureus Went with the relevant drug efficacy study of control cardiovascular and cerebrovascular disease:
(1), Radix Notoginseng
Radix Notoginseng sweet in the mouth warm in nature, little hardship are gone into liver, stomach warp, and eliminating stasis to stop pain is arranged, and the effect of subduing swelling and relieving pain studies have shown that the extensive of its drug effect, and it is better and toxicity is less that Radix Notoginseng is used for cardio-cerebrovascular aspect effect.1, blood pressure lowering
The intravenous injection Radix Notoginseng total arasaponins can make the aortic pressure of Canis familiaris L. reduce, and the diastolic pressure fall is bigger than systolic pressure, and its underpressure and dosage are proportionate.The Radix Notoginseng total arasaponins blood pressure lowering mainly is because of direct blood vessel dilating, also may be relevant with the inhibition cardiac contractility.2, blood fat reducing
Radix Notoginseng total arasaponins is influential to the content of serum lipids, and administration group high density lipoprotein (HDL-C), HDL-C/TC value are all obviously greater than matched group, but serum triglycerides (TC) and T-CHOL (TG) content and matched group comparing difference are not obvious.3, blood sugar regulation
Radix Notoginseng extract has dual regulation to blood glucose, and the mice fasting glucose that can slightly raise also can have hypoglycemic activity preferably to alloxan induced mice hyperglycemia.
Radix Notoginseng total arasaponins has the rising blood glucose effect of significant collaborative glucagon.Panax Notoginseng saponin R g
1The blood glucose increasing effect of tangible antagonism glucagon is arranged, can also reduce the alloxan diabetes mouse blood sugar, and dose-effect relationship is obvious.4, atherosclerosis
Radix Notoginseng total arasaponins is formed with obvious inhibitory action to experimental atherosclerosis rabbit aorta inner membrance speckle, its mechanism of action may with the Radix Notoginseng total arasaponins arterial wall prostaglandin I that raises
2(PGI
2), reduce the plain A of platelet thrombus
2(TXA
2) content, thereby correct modeling rabbit PGI
2-TXA
2Between unbalance, it is relevant to stablize blood vessel internal ring border.(2) Monas cuspurpureus Went
Monas cuspurpureus Went sweet in the mouth warm in nature is gone into liver, spleen, large intestine channel, and blood circulation promoting and blood stasis dispelling is arranged, and the effect of strengthening the spleen to promote digestion for China's traditional zymotic product, is mainly used in the food and medicine aspect.From 1979, extraction separation obtained the synthetic rate-limiting enzyme 3-hydroxyl of cholesterol-3-glutaryl CoA reductase inhibitor from Monas cuspurpureus Went---and since the Monacolin K (being lovastatin), just increasingly extensive and deep to the research of Monas cuspurpureus Went medical value both at home and abroad.
1, blood fat reducing
Hongqu powder (red colouring agent) has prevention and therapeutic effect preferably to hyperlipemia, and anti-atherogenic speckle formation effect is preferably arranged, and dosage becomes positive correlation with drug effect.
The ethanol extraction of Monas cuspurpureus Went has the effect that reduces hyperlipemia Carnis Coturnicis japonicae serum total cholesterol (TC), triglyceride (TG), low density lipoprotein, LDL (LDL-C), and hypolipidemic activity and lovastatin content are proportionate.Research finds that also when as long as the blood concentration of Monacolin constituents reaches 0.001～0.005ug/ml, cholesterol is synthetic will to be suppressed.
In addition, research also finds in the Monas cuspurpureus Went to exist other blood fat reducing active component, and as lecithin etc., the effect for reducing blood fat that shows Monas cuspurpureus Went may be the collaborative result of multicomponent.
2, blood pressure lowering
Monas cuspurpureus Went is influential to hypertension model rat systolic pressure, can reduce the blood pressure of spontaneous hypertension rat (SHR), DOCA-salt type Hypertensive Rats (DHR), but the hypotensive activity to kidney vascular type Hypertensive Rats (RHR) is not obvious, wherein, the hypotensive activity of DHR is better than SHR.DHR is a low renin pattern type, and the prompting Monas cuspurpureus Went has hypotensive activity preferably to the low renin hypertension patient.
The present invention compared with prior art has the following advantages or good effect:
1, generally acknowledge that at present the blood fat reducing active component is a lovastatin in the Monas cuspurpureus Went, more, more deep to this composition Study;
2, Recent study finds to also have other component for reducing blood fat---lecithin in the Monas cuspurpureus Went, and the composition that improves the cardio-cerebrovascular function---daidzein;
Studies show that 3, that Monas cuspurpureus Went effect for reducing blood fat and control cardiovascular and cerebrovascular disease composition and mechanism complexity are not only that single component works, but act on body by multipath;
4, in order to develop the function of Monas cuspurpureus Went blood fat reducing and control cardiovascular and cerebrovascular disease as far as possible all sidedly, clear and definite in Patent right requirement of the present invention: Monas cuspurpureus Went and extract thereof, effective site and effective ingredient (comprise lovastatin, lecithin, daidzein etc. and the Monas cuspurpureus Went discovered from now in to have a blood fat reducing active or improve the composition of cardio-cerebrovascular function) all can be used as raw material.
5, one of main purpose of patent of the present invention be by extensively, in depth study in Radix Notoginseng, the Monas cuspurpureus Went blood fat reducing and the control cardiovascular and cerebrovascular disease composition, be intended to find the compositions of Radix Notoginseng or Radix Notoginseng extract and Monas cuspurpureus Went or Monas cuspurpureus Went extract, wherein each composition has significant synergism, but not.Simply add and
Embodiment 1:
Radix Notoginseng powder (100 order) and Hongqu powder (red colouring agent) (100 order) are in 1: 1 ratio, mix homogeneously.Transfer blood fat, transfer blood pressure, transfer tests such as blood glucose and atherosclerosis.
Embodiment 2:
Radix Notoginseng powder (100 order) and Hongqu powder (red colouring agent) (100 order) are in 1: 2 ratio, mix homogeneously.Transfer blood fat, transfer blood pressure, transfer tests such as blood glucose and atherosclerosis.
Embodiment 3:
Radix Notoginseng powder (100 order) and Hongqu powder (red colouring agent) (100 order) are in 2: 1 ratios, mix homogeneously.Transfer blood fat, transfer blood pressure, transfer tests such as blood glucose and atherosclerosis.
Embodiment 4:
Radix Notoginseng powder (40 order) is with 95% alcohol reflux three times, and the time is respectively 2h, 1h, 1h, merges three times filtrate, reclaims ethanol, extractum, drying for standby.
Hongqu powder (red colouring agent) (40 order) is with 95% alcohol reflux three times, and the time is respectively 2h, 1h, 1h, merges three times filtrate, reclaims ethanol, extractum, drying for standby.
Dry extract is 1. with 2. in 1: 1 ratio, mix homogeneously.Transfer blood fat, transfer blood pressure, transfer tests such as blood glucose and atherosclerosis.
Embodiment 5:
Radix Notoginseng total arasaponins (100 order) and Hongqu powder (red colouring agent) (100 order) are in 1: 10 ratio, mix homogeneously.Transfer blood fat, transfer blood pressure, transfer tests such as blood glucose and atherosclerosis.
Above embodiment is only for the invention will be further described, and the present invention is not subjected to the limitation of embodiment.
Experimental example 1: blood lipid regulation effect research
Test method:
The foundation of 1 rat obesity, hyperlipidemia model: wean male rat, average weight 110g, feed are made high fat high cholesterol diet 47d by oneself, and body weight gain and TC are all apparently higher than negative control group (P＜0.01), and model is successful.
2 lowering blood-fat and reducing weights test: by body weight and TC value the high-fat adiposity rat is divided into 2 groups at random, is high-fat adiposity matched group (O group), is tried the thing group, 10 of every group of rats, negative control group (O
1Group) continues to keep.Tried thing group feed and add and tried object height fat high cholesterol diet, the simple high fat high cholesterol diet of O group feed, O
1The common rat pellet of group feed is fed time 30d.
Blood Lipid such as following table: (mg/100dl) group Mus number (only) TC TG HDL-C O
1Thing 10 81.3 ± 13.9 is tried in 5 47.3 ± 5.0 47.1 ± 18. ± 28.2 ± 6.4 O 10 98.4 ± 21. ± 233.2 ± 88.1 19.6 ± 2.0
149.8 ± 21.8
21.6 ± 4.5: P＜0.01: P＜0.05 (comparing) conclusion with the O group
1, result of the test shows, being tried thing (patent compositions of the present invention) group compares with high-fat adiposity matched group (O group), reduce serum total cholesterol (TC) difference utmost point significance meaning is arranged, reduce serum triglycerides (TG) difference the significance meaning is arranged, and high density lipoprotein increasing-cholesterol (HDL-C) difference does not have the significance meaning, illustrates that said composition has the effect that reduces TC and TG preferably.
2, be 0.6g according to result of the test conversion people taking dose every day, further converting the people, to take lovastatin dosage every day be 4.5mg (is 1.5% to calculate by lovastatin content in the Monas cuspurpureus Went).
3, according to Beijing University's dimension letter XUEZHIKANG JIAONANG (product batch number: 20011209) every of defined contains lovastatin and must not be less than 2.5mg, one time 2, calculate for 2 times on the one, the people takes lovastatin dosage every day and is at least 10.0mg.
4, the people takes lovastatin dosage every day, and XUEZHIKANG JIAONANG approximately is 2 times of patent compositions of the present invention, this shows, each composition has synergism really in the said composition, and we also will really carry out deep drug efficacy study to its synergistic.
Claims (6)
1, the compositions of a kind of prevention or treatment cardiovascular and cerebrovascular disease is a raw material with Radix Notoginseng and Monas cuspurpureus Went, it is characterized in that: in dry matter weight, press Radix Notoginseng: Monas cuspurpureus Went=(10%～90%): (90%～10%) mixed.
2, compositions as claimed in claim 1, its feature in: the fungus that produces Monas cuspurpureus Went can be any in monascus (Monacus anka), Mauve aspergillar (Monacus Purpureus), the monascus that turns white (Monacusalbidus), Bark monascus (Monacus barkeri), smoky gray monascus (Monacusfulignosus), red monascus (Monacus rubervam), rust monascus (Monacusrubiginosus), the monascus that reddens (Monacus serorubescens) and the Mucor shape monascus (Monacusmucoroides).
3, compositions as claimed in claim 1 is characterized in that: Radix Notoginseng (Panax notoginseng) and extract, effective site and effective ingredient all can be used as raw material.
4, compositions as claimed in claim 1 is characterized in that: Monas cuspurpureus Went and extract thereof, effective site and effective ingredient all can be used as raw material.
5, compositions as claimed in claim 1 is characterized in that: said composition can be an acceptable preparation medically, as, tablet, capsule (soft capsule or hard capsule), granule, powder etc.
6, compositions as claimed in claim 1 is characterized in that: said composition can be applicable to health food or food additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021137978A CN1183935C (en) | 2002-05-27 | 2002-05-27 | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021137978A CN1183935C (en) | 2002-05-27 | 2002-05-27 | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1383871A true CN1383871A (en) | 2002-12-11 |
| CN1183935C CN1183935C (en) | 2005-01-12 |
Family
ID=4742812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021137978A Expired - Lifetime CN1183935C (en) | 2002-05-27 | 2002-05-27 | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1183935C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1919214B (en) * | 2005-08-24 | 2010-05-05 | 成都地奥九泓制药厂 | Monascus soft capsule and its preparation method |
| CN102599501A (en) * | 2012-03-15 | 2012-07-25 | 宋靖钢 | Healthcare Hongyang capsule or tablet product for lowering lipid and protecting liver |
| CN103251042A (en) * | 2012-03-08 | 2013-08-21 | 山东德圣医药科技有限公司 | Auxiliary hypolipidemic health-care food |
| CN103493681A (en) * | 2013-09-24 | 2014-01-08 | 成都信息工程学院 | Method for producing medical mycoplasm by using pseudo-ginseng dregs in co-fermentation mode |
| CN103655697A (en) * | 2012-09-26 | 2014-03-26 | 郑州御寿堂健康产业科技发展有限公司 | Product for reducing blood fat and preparation process thereof |
| CN104997823A (en) * | 2014-04-25 | 2015-10-28 | 北京北大维信生物科技有限公司 | Medicinal composition containing Folium Ginkgo, red yeast rice and panax notoginseng, and preparation thereof |
| CN105641509A (en) * | 2016-01-14 | 2016-06-08 | 吕海峰 | Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application |
-
2002
- 2002-05-27 CN CNB021137978A patent/CN1183935C/en not_active Expired - Lifetime
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1919214B (en) * | 2005-08-24 | 2010-05-05 | 成都地奥九泓制药厂 | Monascus soft capsule and its preparation method |
| CN103251042A (en) * | 2012-03-08 | 2013-08-21 | 山东德圣医药科技有限公司 | Auxiliary hypolipidemic health-care food |
| CN102599501A (en) * | 2012-03-15 | 2012-07-25 | 宋靖钢 | Healthcare Hongyang capsule or tablet product for lowering lipid and protecting liver |
| CN102599501B (en) * | 2012-03-15 | 2013-11-06 | 宋靖钢 | Healthcare Hongyang capsule or tablet product for lowering lipid and protecting liver |
| CN103655697A (en) * | 2012-09-26 | 2014-03-26 | 郑州御寿堂健康产业科技发展有限公司 | Product for reducing blood fat and preparation process thereof |
| CN103493681A (en) * | 2013-09-24 | 2014-01-08 | 成都信息工程学院 | Method for producing medical mycoplasm by using pseudo-ginseng dregs in co-fermentation mode |
| CN104997823A (en) * | 2014-04-25 | 2015-10-28 | 北京北大维信生物科技有限公司 | Medicinal composition containing Folium Ginkgo, red yeast rice and panax notoginseng, and preparation thereof |
| CN105641509A (en) * | 2016-01-14 | 2016-06-08 | 吕海峰 | Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1183935C (en) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1259935C (en) | Medicine for treating hyperlipemia | |
| CN104667283B (en) | A kind of compound medicine combination for treating dyslipidemia and atherosclerosis | |
| CN100336517C (en) | Red rice and gingko leaf composition for preventing and treating cardiovascular and cerebrovascular disease and its application | |
| CN1954686A (en) | Tea beverage for reducing blood fat and its preparation method | |
| CN1183935C (en) | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases | |
| AU2013368749B2 (en) | Medical formulation for treating hypercholesterolemia | |
| CN1539475A (en) | Combination of natural products for curing hyperlipemia, atherosclerosis and relevant disease | |
| CN1173707C (en) | Medicinal composition containing baicalin and caffoeoylchinic acid | |
| CN1213747C (en) | Specific therapeutic composition for treating AIDS | |
| CN105641509A (en) | Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application | |
| CN105943583B (en) | Sweet wormwood herb and red yeast rice composition and application thereof | |
| KR100532556B1 (en) | Composition for treating obesity and constipation containing extract of pine needle, green tea and black tea as an active ingredient | |
| CN101264091A (en) | Blood-fat reducing composition and uses thereof | |
| CN1660207A (en) | Preparation of health care for reducing blood fat and cholesterol, and producing method | |
| CN112999216B (en) | A pharmaceutical composition containing tylosin for treating diabetic cardiomyopathy | |
| CN110013474A (en) | The new application of fenofibrate and drug for new application | |
| CN1293914C (en) | Health care medicinal composition for improving sleeping and preparation preocess thereof | |
| CN115590851B (en) | Application of 4- (4-diethylamino-1-methylbutylamino) -7-chloroquinoline derivative in preparation of medicines for treating obesity | |
| CN102161619B (en) | Ferulic acid Jiangtang compound salt as well as preparation method and application thereof | |
| CN101856403B (en) | Medicinal composition, preparation method thereof and pharmaceutical application | |
| CN101053598A (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
| KR20090027383A (en) | Composition for preventing or treating hyperlipidemia | |
| CN103316004B (en) | Pharmaceutical composition used for preventing and controlling metabolic syndrome and application thereof | |
| CN105213398B (en) | A kind of pharmaceutical composition for treating diabetes | |
| CN1251684C (en) | Health care food for relaxing hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING YUNDA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YUNDA SCIENCE +. TECHNOLOGY CO., LTD. Effective date: 20071026 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20071026 Address after: 100021 Beijing city Chaoyang District East sanhuan Road No. 21 Yijingjiayuan No. 1 building 10 room G Patentee after: Beijing Yunda Pharmaceutical Co. Ltd. Address before: 650106 No. 59, medical Road, hi tech Industrial Development Zone, Yunnan, Kunming Patentee before: Yunda Science &. Technology Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: MENG QINGFA Free format text: FORMER OWNER: BEIJING YUEDA PHARMACEUTICAL CO., LTD. Effective date: 20141209 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100021 CHAOYANG, BEIJING TO: 518100 SHENZHEN, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141209 Address after: 518100 Dragon Pavilion 12E, dragon pearl garden, Buji Town, Longgang District, Guangdong, Shenzhen Patentee after: Meng Qingfa Address before: 100021 Beijing city Chaoyang District East sanhuan Road No. 21 Yijingjiayuan No. 1 building 10 room G Patentee before: Beijing Yunda Pharmaceutical Co. Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20050112 |
|
| CX01 | Expiry of patent term |